NEUEHEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.11 USD | -3.54% |
|
+4.98% | -19.92% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 2,162 | 407.8 | 60.66 | 49.02 | - |
| Enterprise Value (EV) 1 | 1,062 | 232.3 | 60.66 | -185.1 | 49.02 |
| P/E ratio | -1.14 x | -0.27 x | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 0.54 x | 0.17 x | 0.05 x | 0.05 x | 0.04 x |
| EV / Revenue | 0.26 x | 0.1 x | 0.05 x | -0.18 x | 0.04 x |
| EV / EBITDA | -0.98 x | -0.99 x | -7.15 x | -8.99 x | 1.21 x |
| EV / FCF | 20,568,053 x | 1,121,774 x | - | - | - |
| FCF Yield | 0% | 0% | - | - | - |
| Price to Book | 1.89 x | -2.03 x | - | - | - |
| Nbr of stocks (in thousands) | 7,857 | 7,844 | 7,951 | 8,023 | - |
| Reference price 2 | 275.2 | 51.99 | 7.630 | 6.110 | 6.110 |
| Announcement Date | 3/2/22 | 3/1/23 | 3/6/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 4,029 | 2,412 | 1,161 | 1,008 | 1,129 |
| EBITDA 1 | - | -1,081 | -233.5 | -8.48 | 20.6 | 40.6 |
| EBIT 1 | - | -1,198 | -622.2 | -577 | -66.8 | -44.7 |
| Operating Margin | - | -29.74% | -25.8% | -49.71% | -6.63% | -3.96% |
| Earnings before Tax (EBT) | - | -1,205 | -634.3 | - | - | - |
| Net income | -248.4 | -1,185 | -1,495 | - | - | - |
| Net margin | - | -29.41% | -61.99% | - | - | - |
| EPS | -437.6 | -241.6 | -190.4 | - | - | - |
| Free Cash Flow | - | 51.64 | 207.1 | - | - | - |
| FCF margin | - | 1.28% | 8.58% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/18/21 | 3/2/22 | 3/1/23 | 3/6/24 | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,079 | 962.3 | 1,836 | 1,577 | 1,632 | 551.4 | 756.3 | 747.7 | 269.4 | 292.9 | 253.8 | 261.9 | 238 | 254.3 |
| EBITDA 1 | -245.9 | -790.1 | -74.83 | -194.9 | -82.93 | -108.5 | -35.05 | 6.413 | 1.205 | -10.36 | 6.4 | 13.2 | 10.4 | -9.4 |
| EBIT 1 | -296.3 | -820 | -177 | -248.1 | -252.7 | -186.1 | -85.75 | -23.41 | -462.8 | -45.94 | -15.7 | -8.7 | -11.4 | -31.1 |
| Operating Margin | -27.47% | -85.21% | -9.64% | -15.74% | -15.48% | -33.74% | -11.34% | -3.13% | -171.78% | -15.68% | -6.19% | -3.32% | -4.79% | -12.23% |
| Earnings before Tax (EBT) | -296.6 | -821.7 | -177.4 | -248.4 | -257.6 | -192.5 | - | - | - | - | - | - | - | - |
| Net income | -300.7 | -814.5 | -204.2 | -284.1 | -315.8 | -691.2 | -186.9 | -125 | - | - | - | - | - | - |
| Net margin | -27.87% | -84.64% | -11.12% | -18.02% | -19.34% | -125.34% | -24.71% | -16.72% | - | - | - | - | - | - |
| EPS | -38.40 | -103.2 | -25.60 | -36.00 | -40.00 | -88.00 | -24.00 | -15.70 | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/2/22 | 5/4/22 | 8/10/22 | 11/9/22 | 3/1/23 | 5/9/23 | 8/9/23 | 11/7/23 | 3/6/24 | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,100 | 176 | - | 234 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 51.6 | 207 | - | - | - |
| ROE (net income / shareholders' equity) | - | -369% | -317% | - | 32.3% | - |
| ROA (Net income/ Total Assets) | - | -43.8% | -36.2% | - | -8.65% | - |
| Assets | - | 2,705 | 4,132 | - | - | - |
| Book Value Per Share | - | 146.0 | -25.60 | - | - | - |
| Cash Flow per Share | - | 16.70 | 29.90 | - | - | - |
| Capex | - | 30.4 | 27.4 | - | - | - |
| Capex / Sales | - | 0.75% | 1.14% | - | - | - |
| Announcement Date | 3/18/21 | 3/2/22 | 3/1/23 | 3/6/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
6.11
USD
Average target price
8
USD
Spread / Average Target
+30.93%
| 1st Jan change | Capi. | |
|---|---|---|
| -19.92% | 49.02M | |
| +6.49% | 50.92B | |
| +1.35% | 48.11B | |
| +9.53% | 42.2B | |
| +6.55% | 39.71B | |
| +19.34% | 37.78B | |
| +2.84% | 30.07B | |
| -7.77% | 27.56B | |
| -18.42% | 24.71B | |
| +6.89% | 21.99B |
- Stock Market
- Equities
- NEUE Stock
- Financials NeueHealth, Inc.
